文献速递免疫规划慢病防控与筛查卫生政策与健康促进

阿拉伯国家宫颈癌预防规划:突尼斯案例的策略与成本最小化研究

National cervical cancer prevention program in the Arab States: Strategies and cost-minimization study of the Tunisian case.
PubMed 文献 · Vaccine · 2018-07-05

本研究针对突尼斯宫颈癌预防规划,采用成本最小化分析比较两种方法:根据WHO建议对年轻青少年接种两剂抗HPV疫苗的一级预防,以及按三种时间间隔进行巴氏涂片检查的二级预防,计算每避免一例宫颈癌的平均增量成本。结果显示,通过GAVI支持的全国疫苗接种规划每避免一例宫颈癌的增量成本最低(1803美元),其次为10年间隔筛查(8219美元)、5年间隔筛查(14567美元)、3年间隔筛查(20479美元),而按厂商市场价接种的全国疫苗规划成本最高(36854美元)。结论认为,目前抗HPV全国疫苗接种规划联合5年间隔宫颈癌筛查是突尼斯最具成本效果的预防策略。

要点

  • 通过GAVI支持的全国疫苗接种规划每避免一例宫颈癌的增量成本为1803美元。
  • 按10年、5年、3年间隔的宫颈癌筛查每避免一例宫颈癌的增量成本分别为8219、14567、20479美元。
  • 按厂商市场价的全国疫苗接种规划每避免一例宫颈癌的增量成本为36854美元。

核心结论

  • 目前,抗HPV全国疫苗接种规划联合5年间隔宫颈癌筛查是突尼斯最具成本效果的宫颈癌预防策略。

研究设计与样本

  • 本研究采用成本最小化分析,估算突尼斯全国宫颈癌预防规划的成本,比较一级预防(根据WHO建议对年轻青少年接种两剂抗HPV疫苗)与二级预防(按三种时间间隔进行巴氏涂片检查)两种方案。

主要发现

  • 每避免一例宫颈癌的增量成本按升序排列为:通过GAVI支持的全国疫苗接种规划1803美元;10年间隔宫颈癌筛查8219美元;5年间隔宫颈癌筛查14567美元;3年间隔宫颈癌筛查20479美元;按厂商市场价的全国疫苗接种规划36854美元。

临床怎么用

  • 本研究为突尼斯决策者提供了结构化规划和成本分摊的基础,以确保宫颈癌预防策略的有效推广。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Arab states geographic region is marked by a low to moderate cervical cancer screening coverage rates and the absence of national human papillomavirus (HPV) vaccination programs, except for the United Arab Emirates. Knowing that the HPV prevalence among Tunisian woman is estimated to 4.9/100 000 according to the "HPV Center" data, this study aims to estimate the cost of a national cervical cancer prevention program in Tunisia using either the primary prevention method (the two-dose schedule anti-HPV vaccine according to the WHO recommendation for young adolescents) or the secondary prevention method (the Pap smear test according to three time-lapse periodicity). METHODS: The mean incremental cost of one avoided cervical cancer case was calculated for each prevention scenario. RESULTS: The ascending incremental costs by avoided cervical cancer case are: 1- the national vaccination program through the GAVI support ($ 1803), 2- the cervical cancer screening according to 10-year periodicity ($ 8219), 3- the cervical cancer screening according to 5-year periodicity ($ 14,567), 4- the cervical cancer screening according to 3-year periodicity ($ 20,479), 5- and finally the national vaccination program according to the manufacturer marketed price ($ 36,854). CONCLUSION: Currently, the anti-HPV national vaccination program combined with cervical cancer screening according to 5-year periodicity present the best cost-effective strategy for cervical cancer prevention in Tunisia. This study gives Tunisian decision makers a basis for structured planning and cost apportionment to ensure effective roll-out of the cervical cancer prevention strategies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gamaoun R. National cervical cancer prevention program in the Arab States: Strategies and cost-minimization study of the Tunisian case. Vaccine. 2018. PMID: 29983258. doi:10.1016/j.vaccine.2018.06.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。